Korea-based LegoChem Biosciences (LCB) was started in 2006 with the objective to accelerate discovery and development of new small molecule drugs. The company is committed to building sustainable pipelines in therapeutic areas of antibiotics, anti-coagulants, anti-cancer and antibody-drug conjugate (ADC) platform technology.
Traditionally, drugs are conjugated at lysine or cysteine residues in antibody, the result of which is inseparable mixtures. Moreover, majority of the current methods employ thiol-maleimide conjugation and the resulting products are unstable thiol-maleimide conjugates (easily dissociated into thiol and maleimide). LCB is working on a technology that consists of site-specific functionalization (to avoid mixture generation) and orthogonal drug conjugation step (which avoids the thiol-maleimide route).
It received the BioSpectrum Asia Pacific Bioscience Industry Emerging Company of the Year Award for 2012.
LegoChem Biosciences anticipates that its ADC technology will define a new paradigm, particularly in the area of anti-cancer, and play a pivotal role in the field of new drug R&D, both in Korea and across the world. Currently, it has 12 projects and the leading ones are second generation oxazolidinone antibiotics, anti-coagulants FXa inhibitor and next generation ADC platform technology.